EcoDrugPlus

Adrenoceptor Alpha 2b

Ensembl ID : ENSOJAG00000008321
Gene Symbol: ADRA2B
1 Cross references
174 Possible Orthologues:

Adrenoceptor Alpha 2b

Ensembl ID : ENSOJAG00000007446
Gene Symbol: ADRA2B
1 Cross references
149 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSOJAG00000016469
Gene Symbol: ADRA2C
1 Cross references
157 Possible Orthologues:

Adrenoceptor Alpha 2c

Ensembl ID : ENSOJAG00000000011
Gene Symbol: ADRA2C
1 Cross references
160 Possible Orthologues:

Adrenoceptor Beta 1

Ensembl ID : ENSOJAG00000011751
Gene Symbol: ADRB1
1 Cross references
161 Possible Orthologues:

Adrenoceptor Beta 2

Ensembl ID : ENSOJAG00000008607
Gene Symbol: ADRB2
1 Cross references
192 Possible Orthologues:

Adrenoceptor Beta 2, Surface A

Ensembl ID : ENSOJAG00000007009
Gene Symbol: ADRB2A
1 Cross references
195 Possible Orthologues:

Adrenoceptor Beta 3a

Ensembl ID : ENSOJAG00000019794
Gene Symbol: ADRB3A
1 Cross references
196 Possible Orthologues:

Aldo-Keto Reductase Family 1 Member B

Ensembl ID : ENSOJAG00000021401
Gene Symbol: AKR1B1
1 Cross references
336 Possible Orthologues:

Aldo-Keto Reductase Family 1, Member B1 (Aldose Reductase), Tandem Duplicate 1

Ensembl ID : ENSOJAG00000021486
Gene Symbol: AKR1B1.1
1 Cross references
338 Possible Orthologues:

Aldo-Keto Reductase Family 1, Member B1 (Aldose Reductase), Tandem Duplicate 1

Ensembl ID : ENSOJAG00000021393
Gene Symbol: AKR1B1.1
1 Cross references
337 Possible Orthologues:

Aldo-Keto Reductase Family 1, Member B1 (Aldose Reductase), Tandem Duplicate 2

Ensembl ID : ENSOJAG00000021209
Gene Symbol: AKR1B1.2
1 Cross references
343 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).